

INDEPENDENT AUDITOR'S REPORT

To the Members of Suraksha Diagnostic Private Limited

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying Consolidated Financial Statements of Suraksha Diagnostic Private Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), which comprise the consolidated Balance Sheet as at March 31, 2022, and the Consolidated Statement of Profit and Loss, and the Consolidated Statement of Cash flows for the year then ended, and notes to the Consolidated Financial Statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the Consolidated Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Consolidated Financial Statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with Accounting Standards prescribed under section 133 of the Act read Companies (Accounts) Rules, 2014 as amended and other accounting principles generally accepted in India, of their consolidated state of affairs of the Group as at March 31, 2022, of Consolidated profit, and its Consolidated Cash Flows for the year then ended.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the Consolidated Financial Statements in India in terms of Code of Ethics issued by Institute of Chartered Accountant of India ("ICAI"), and the relevant provisions of the Act and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information Other than the Consolidated Financial Statements and Auditor's Report Thereon

The Holding Company's Board of Directors is responsible for the other information. The other information comprises the Director's report but does not include the Consolidated Financial Statements and our auditor's report thereon. The Director's report is expected to be made available to us after the date of this auditor's report.

Our opinion on the Consolidated Financial Statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the Consolidated Financial Statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is



materially inconsistent with the Consolidated Financial Statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

When we read the Director's report if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance under SA 720 'The Auditor's responsibilities Relating to Other Information'.

Responsibilities of Management for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the preparation and presentation of these Consolidated Financial Statements in term of the requirements of the Act that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated Financial Statements by the Directors of the Holding Company, as aforesaid.

In preparing the Consolidated Financial Statements, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing ("SAs") will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Statements.

We give in "Annexure A" a detailed description of Auditor's responsibilities for Audit of the Consolidated Financial Statements.



Other Matters

We did not audit the financial statements of two subsidiaries, whose financial statements reflect total assets of Rs. 36.14 lacs as at March 31, 2022, total revenues of Rs. Nil and net cash outflows amounting to Rs.8.17 lacs for the year ended on that date, as considered in the Consolidated Financial Statements. These financial statements are unaudited and have been furnished to us by the Management and our opinion on the Consolidated Financial Statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, and our report in terms of sub-section (3) of Section 143 of the Act in so far as it relates to the aforesaid subsidiaries, is based solely on such unaudited financial statements. In our opinion and according to the information and explanations given to us by the Management, these financial statements are not material to the Group.

Our opinion on the Consolidated Financial Statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matters with respect to our reliance on the financial statements certified by the Management.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, we report, to the extent applicable, that:
 - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid Consolidated Financial Statements.
 - b. In our opinion, proper books of account as required by law relating to preparation of the aforesaid Consolidated Financial Statements have been kept so far as it appears from our examination of those books and the reports of the other auditors.
 - c. The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss, and the Consolidated Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the Consolidated Financial Statements.
 - d. In our opinion, the aforesaid Consolidated Financial Statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e. On the basis of the written representations received from the directors of the Holding Company as on March 31, 2022 taken on record by the Board of Directors of the Holding Company, none of the directors of the Holding Company is disqualified as on March 31, 2022 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f. With respect to the adequacy of internal financial controls with reference to financial statements of the Group and the operating effectiveness of such controls, refer to our separate report in "Annexure B".
 - g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditor's) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:



- i. The Consolidated Financial Statements disclose the impact of pending litigations on the consolidated financial position of the Group - Refer Note 31 to the Consolidated Financial Statements.
 - ii. The Group did not have any material foreseeable losses on long-term contracts including derivative contracts.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Holding Company and its subsidiaries incorporated in India.
 - iv.
 - (1) The Management of the Holding Company have represented that, to the best of their knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Holding Company or any of such subsidiaries to or in any other person(s) or entity(ies), including foreign entities with the understanding, whether recorded in writing or otherwise, as on the date of this audit report, that such parties shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Holding Company or any of such subsidiaries ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - (2) The Management of the Holding Company have represented that, to the best of their knowledge and belief, no funds have been received by the Holding Company or any of such subsidiaries from any person(s) or entity(ies), including foreign entities with the understanding, whether recorded in writing or otherwise, as on the date of this audit report, that the Holding Company or any of such subsidiaries shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - (3) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances performed by us, and according to the information and explanations provided to us by the Management of the Holding company in this regard nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e) as provided under (1) and (2) above, contain any material mis-statement.
 - v. The Holding Company has neither declared nor paid any dividend during the year. The subsidiaries are in the form of Limited Liability Partnership and hence the said provisions of the Act are not applicable on them.
2. In our opinion, according to information, explanations given to us, the provisions of Section 197 of the Act and the rules thereunder are not applicable to the Holding Company as it is a Private Limited Company. The subsidiaries are in the form of Limited Liability Partnership and hence the said provisions of the Act are not applicable on them.



MSKA & Associates

Chartered Accountants

3. With respect to the matters specified in clause (xxi) of paragraph 3 and paragraph 4 of the Companies (Auditor's Report) Order, 2020 ("CARO"/ "the Order") issued by the Central Government in terms of Section 143(11) of the Act, according to the information and explanations given to us, subsidiaries are in the form of Limited Liability Partnership and hence the said provisions of the Act are not applicable on them.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No. 105047W




Puneet Agarwal
Partner
Membership No. 064824
UDIN: 22064824AXOPVR1603

Place: Kolkata
Date: 30.09.2022

ANNEXURE A TO THE INDEPENDENT AUDITOR'S REPORT ON EVEN DATE ON THE CONSOLIDATED FINANCIAL STATEMENTS OF SURAKSHA DIAGNOSTIC PRIVATE LIMITED

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Statements, including the disclosures, and whether the Consolidated Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the Consolidated Financial Statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of such entities included in the Consolidated Financial Statements of which we are the independent auditors. For the other entities included in the Consolidated Financial Statements, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.



MSKA & Associates

Chartered Accountants

We communicate with those charged with governance of the Holding Company and such other entities included in the Consolidated Financial Statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No. 105047W



Puneet Agarwal
Partner
Membership No. 064824
UDIN: 22064824AXOPVR1603

Place: Kolkata
Date: 30.09.2022

ANNEXURE B TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE CONSOLIDATED FINANCIAL STATEMENTS OF SURAKSHA DIAGNOSTIC PRIVATE LIMITED

[Referred to in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements' in the Independent Auditors' Report of even date to the Members of Suraksha Diagnostic Private Limited on the Consolidated Financial Statements for the year ended March 31, 2022]

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

Opinion

In conjunction with our audit of the Consolidated Financial Statements of the Company as of and for the year ended March 31, 2022, we have audited the internal financial controls with reference to Consolidated Financial Statements of Suraksha Diagnostic Private Limited (hereinafter referred to as "the Holding Company") as of that date.

In our opinion, and to the best of our information and according to the explanations given to us, the Holding Company, have, in all material respects, an adequate internal financial controls with reference to Consolidated Financial Statements and such internal financial controls with reference to Consolidated Financial Statements were operating effectively as at March 31, 2022, based on the internal control with reference to Consolidated Financial Statements criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India ("the ICAI").

Management's Responsibility for Internal Financial Controls

The Board of Directors of the Holding company are responsible for establishing and maintaining internal financial controls based on the internal control with reference to Consolidated Financial Statements criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Holding Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the internal financial controls with reference to Consolidated Financial Statements of the Holding company, based on our audit. We conducted our audit in accordance with the Guidance Note issued by the ICAI and the Standards on Auditing prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements



and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to Consolidated Financial Statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to Consolidated Financial Statements and their operating effectiveness. Our audit of internal financial controls with reference to Consolidated Financial Statements included obtaining an understanding of internal financial controls with reference to Consolidated Financial Statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the Consolidated Financial Statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to Consolidated Financial Statements of the Holding company.

Meaning of Internal Financial Controls With Reference to Consolidated Financial Statements

A company's internal financial control with reference to Consolidated Financial Statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Consolidated Financial Statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to Consolidated Financial Statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of Consolidated Financial Statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the Consolidated Financial Statements.

Inherent Limitations of Internal Financial Controls With Reference to Consolidated Financial Statements


Because of the inherent limitations of internal financial controls with reference to Consolidated Financial Statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to Consolidated Financial Statements to future periods are subject to the risk that the internal financial control with reference to Consolidated Financial Statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.




Other Matters

Our aforesaid reports under Section 143(3)(i) of the Act on the adequacy and operating effectiveness of the internal financial controls with reference to Consolidated Financial Statements insofar as it relates to the Group does not include the reports of two subsidiary entities as the said reporting on internal financial control is not applicable to those subsidiaries.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No. 105047W


Puneet Agarwal
Partner
Membership No. 064824
UDIN: 22064824AXOPVR1603



Place: Kolkata
Date: 30/09/2022

Particulars	Notes	As at 31-Mar-2022	As at 31-Mar-2021
Equity & Liabilities			
Shareholder's Fund			
Share Capital	3	852.86	852.86
Reserves & Surplus	4	14,144.46	11,769.49
Total Shareholder's Fund		14,997.32	12,622.35
Liabilities			
Non - Current Liabilities			
(a) Long-Term Borrowings	5	1,228.13	992.85
(b) Deferred Tax Liability (Net)	6	1,004.71	982.91
(c) Long-Term Provisions	7	31.14	11.01
Total Non-Current Liabilities		2,263.98	1,986.77
Current Liabilities			
(a) Short-Term Borrowings	8	673.81	650.21
(b) Trade Payables			
- Total outstanding dues of micro enterprises and small enterprises	9	4.29	4.63
- Total outstanding dues of creditors other than micro enterprises and small enterprises	9	1,383.03	1,255.77
(c) Other Current Liabilities	10	628.69	584.70
(d) Short-Term Provisions	11	120.60	0.30
Total Current Liabilities		2,810.42	2,495.61
Total Equity & Liabilities		20,071.72	17,104.73
Assets			
Non-Current Assets			
(a) Property, Plant and Equipment	12	11,755.30	11,691.31
(b) Other Intangible Assets	13	175.38	207.93
(c) Capital Work-in-Progress	12	123.51	0.86
(d) Intangible Assets Under Development	13	-	15.05
(e) Long-Term Loans & Advances	14	197.06	180.00
(f) Other Non-Current Assets	15	5,639.81	2,275.54
Total Non-Current Assets		17,891.06	14,370.69
Current Assets			
(a) Current Investments	16	-	541.18
(b) Inventories	17	622.53	444.50
(c) Trade Receivables	18	756.70	599.53
(d) Cash and Bank Balances			
- Cash and cash equivalents	19	257.47	293.21
- Other bank balances	19	25.00	149.83
(e) Short-Term Loans & Advances	20	518.96	705.79
Total Current Assets		2,180.66	2,734.04
Total Assets		20,071.72	17,104.73

Summary of Significant Accounting Policies 2

The accompanying notes are an integral part of the consolidated financial statements.


As per our report of even date
For M S K A & Associates
Chartered Accountants

ICAI Firm Registration No.:105047W


Puneet Agarwal
Partner
Membership No: 064824



Suraksha Diagnostic Private Limited
for and on behalf of the Board of Directors of


Dr. Somnath Chatterjee
Director
DIN: 00137075


Ritu Mittal
Director
DIN: 00165886

Place: Kolkata
Date: 30-09-2022



Suraksha Diagnostic Private Limited
CIN:U85110WB2005PTC102265
Statement of Profits and Loss for the year ended March 2022
(all amounts in INR Lacs, unless stated otherwise)

Particulars	Notes	For the year ended 31 March 2022	For the year ended 31 March 2021
Income			
I Revenue from Operations	21	22,319.25	14,000.57
II Other Income	22	230.34	137.60
III Total Income (I + II)		22,549.59	14,138.17
IV Expenses:			
Cost of Materials Consumed	23	6,040.49	2,600.96
Employee Benefits Expenses	24	3,413.94	2,492.09
Finance Costs	25	152.56	156.02
Depreciation and Amortisation Expenses	26	1,509.13	1,571.16
Other Expenses	27	8,114.23	6,680.56
V Total Expenses		19,230.35	13,500.79
VI Profit before Tax (III - V)		3,319.24	637.38
VII Tax Expenses :			
Current Tax (Net of MAT credit utilized amounting to Rs.21.28 lacs (Previous Year Rs.173.19 lacs)		922.47	133.17
Tax Relating to Earlier Years		-	5.46
Deferred Tax	6	21.80	(144.76)
		944.27	(6.13)
VIII Profit After Tax for the Year (VIII - IX)		2,374.97	643.51
Earnings per equity share (Nominal value of Rs 100/-)	28		
- Basic		344.20	93.26
- Diluted		278.47	75.45

The accompanying notes are an integral part of the consolidated financial statements.

As per our report of even date
For M S K A & Associates
Chartered Accountants
CAI Firm Registration No.: 105047W

Puneet Agarwal
Partner
Membership No: 064824

Place: Kolkata
Date: 30-09-2022



Suraksha Diagnostic Private Limited
for and on behalf of the Board of Directors of

Dr. Sannat Chatterjee
Director
DIN: 00137075

Ritu Mittal
Director
DIN: 00165886



Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
A Cash Flow From Operating Activities		
Profit before Tax	3,319.24	637.38
Adjustment to reconcile profit before tax to net cash flows		
Depreciation and amortisation expense	1,509.13	1,571.16
Interest Income	(181.13)	(59.68)
Loss on Sale of Assets	141.48	245.03
Net gain on sale of current investments	(0.29)	(29.42)
Dividend income from mutual funds	(0.64)	(1.46)
Provision for doubtful debts	-	284.38
Liabilities / Provisions no longer required now Written back	(37.07)	(33.71)
Interest Expenses	152.56	156.01
Operating profit before working capital changes	4,903.28	2,769.69
Movement in working capital:		
(Increase)/Decrease in Inventory	(178.02)	100.12
(Increase)/Decrease in Trade Receivables	(116.26)	(284.39)
(Increase)/Decrease in Loans and Advances & Other Assets	(194.51)	(62.80)
Increase/(Decrease) in Trade Payables	123.08	(33.06)
Increase/(Decrease) in Other Liabilities	102.18	0.63
Increase/(Decrease) in Provision	37.98	11.31
Cash generated from operations	4,677.73	2,501.50
Income Tax Payments (including MAT Credit and net of refunds)	443.64	150.33
Net Cash generated from operating activities	A 4,234.09	2,351.17
B Cash Flows from Investing Activities		
Purchase of property, plant & equipment and intangibles assets including capital work in progress and capital advances	(1,924.89)	(1,540.06)
Payment of purchase consideration against acquisition of property, plant & equipment	-	(335.99)
Proceeds from sale of current investments	34.41	25.00
Purchase of current investments	541.47	557.78
Dividend income from Investments	-	(531.35)
Investment in fixed deposits (having original maturity of more than three months)	0.64	1.46
Interest Received	(3,211.30)	(1,007.35)
Net Cash used in investing activities	B (4,378.54)	(2,770.83)
C Cash flow from Financing Activities		
Increase in Term Loans for Medical Equipments & Car Loan	278.78	323.40
(Decrease)/Increase in Working Capital Term Loan	(19.90)	159.70
Interest Paid	(150.17)	(162.04)
Net Cash generated from Financing activities	C 108.71	321.06
Net increase/(decrease) in cash and cash equivalent	(A+B+C) (35.74)	(98.60)
Cash and Cash Equivalents at beginning of the year	293.21	391.81
Cash and Cash Equivalents at end of the year	257.47	293.21
Components of Cash and Cash Equivalent		
Cash in hand	30.45	54.89
Balance with Bank on Current Accounts	213.06	219.92
Prepaid Bank Balances	13.96	18.40
	257.47	293.21

Notes

- The above Cash Flow Statement has been prepared under the "Indirect Method" as stated in Accounting Standard 3 in 'Cash Flow Statement' prescribed under Companies Act, 2013
- Negative figures has been shown in bracket
- Previous Period's Figure have been regrouped/rearranged wherever necessary to confirm with current year's presentation

As per our report of even date
 For M S K A & Associates
 Chartered Accountants
 ICAI Firm Registration No. 105047W

 Puneet Agarwal
 Partner
 Membership No. 064824

For and on behalf of the Board of Directors of
 Suraksha Diagnostic Private Limited

Dr Somnath Chatterjee
 Director
 DIN: 00137075


 Ritu Mittal
 Director
 DIN: 00165886

Place: Kolkata
 Date: 30-09-2022



3 Share capital

Particulars	As at March 31, 2022	As at March 31, 2021
Authorised :		
12,20,000 equity shares of Rs. 100/- each (March 31, 2021: 12,20,000 equity shares of Rs.100/- each)	1,220.00	1,220.00
1,80,000 0.0001% Compulsorily Convertible Preference Shares of Rs. 100 each (March 31, 2021: 1,80,000 0.0001% Compulsorily Convertible Preference shares of Rs. 100/- each)	180.00	180.00
Total	1,400.00	1,400.00
Issued Subscribed and Fully Paid Up Shares :		
Equity Share Capital		
6,90,000 (Previous Year: 6,90,000) Equity Shares of Rs. 100/- each	690.00	690.00
Preference Share Capital		
1,62,859 (Previous Year: 1,62,859) 0.0001% Compulsory Convertible Cumulative Preference Share of Rs.100/-each	162.86	162.86
Total	852.86	852.86

(a) (i) Reconciliation of no. of equity shares & amount outstanding at the beginning and at the end of the year

Particulars	As at March 31, 2022		As at March 31, 2021	
	No. of Shares	Amount	No. of Shares	Amount
Equity Shares outstanding at the beginning of the year	6,90,000	690.00	6,90,000	690.00
Equity Shares Outstanding at the end of the year	6,90,000	690.00	6,90,000	690.00

(ii) Reconciliation of no. of preference shares outstanding at the beginning and at the end of the year

Particulars	As at March 31, 2022		As at March 31, 2021	
	No. of Shares	Amount	No. of Shares	Amount
0.0001% Compulsorily Convertible Preference Shares outstanding at the beginning of the year	1,62,859	162.86	1,62,859	162.86
0.0001% Compulsorily Convertible Preference Shares outstanding at the end of the year	1,62,859	162.86	1,62,859	162.86

(b) (i) Right, preferences and restrictions attached to equity shares

The Holding Company has only one class of equity share having face value of Rs.100/- each (March 31, 2021: Rs.100/- each). Each shareholder is entitled to one vote per share held. The Holding Company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the General Meeting. The above shareholding represent the legal ownership of shares.

In the event of liquidation of the Holding Company, the equity shareholders shall be entitled to receive remaining assets of the Holding Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders. Equity Shares held by OrbiMed Asia II Mauritius FDI Investments Limited in the Holding Company carry certain protective rights under the terms of the Shareholders Agreement.

(ii) Rights, preferences and restrictions attached to 0.0001% Compulsorily Convertible Preference Shares

Each 0.0001% Compulsorily Convertible Preference Shares has a face value of Rs 100/- (March 31, 2021: Rs.100/- each) and are convertible into 1(One) Equity Share of Rs 100 each at such time as required but mandatorily convertible after 19 years. The preference shares carry a dividend of 0.0001% per annum on the face value to be paid out of profits of the Holding Company. The preference share was issued on 27 March 2017.

(c) (i) Details of Equity Shares held by each Shareholder holding more than 5% of the Holding Company :

Name of Shareholder	As at March 31, 2022		As at March 31, 2021	
	No. of Shares held	% of holding	No. of Shares held	% of holding
Kishan Kumar Kejriwal	76,945	11.15%	76,945	11.15%
Dr. Somnath Chatterjee	66,000	9.57%	49,976	7.24%
Ritu Mittal	1,57,769	22.87%	1,21,661	17.63%
Satish Verma	1,33,689	19.38%	1,59,275	23.08%
Tinni Investment Limited	38,512	5.58%	38,512	5.58%
OrbiMed Asia II Mauritius FDI Investments Limited	1,34,587	19.51%	1,34,587	19.51%
Total	6,07,502	88.06%	5,80,956	84.19%

(ii) Details of 0.0001% Compulsorily Convertible Preference Shares held by each Shareholder holding more than 5% of the Holding Company :

Shareholders Name	As at 31-Mar-2022		As at 31-Mar-2021	
	No. of Shares held	% of holding	No. of Shares held	% of holding
OrbiMed Asia II Mauritius FDI Investments Limited	1,62,859	100.00%	1,62,859	100.00%
Total	1,62,859	100.00%	1,62,859	100.00%

(d) Disclosure of shareholding of promoters

Shareholders Name	As at 31-Mar-2022		As at 31-Mar-2021	
	No. of Shares held	% of holding	No. of Shares held	% of holding
Kishan Kumar Kejriwal	76,945	11.15%	76,945	11.15%
Dr. Somnath Chatterjee	66,000	9.57%	49,976	7.24%
Ritu Mittal	1,57,769	22.87%	1,21,661	17.63%
Satish Verma	1,33,689	19.38%	1,59,275	23.08%
Total	4,34,403	62.97%	4,07,857	59.10%

(e) Disclosure of % of change in shareholding of promoters

Shareholders Name	As at 31-Mar-2022		As at 31-Mar-2021	
	No. of Shares held	% of Change in Shareholding	No. of Shares held	% of Change in Shareholding
Dr. Somnath Chatterjee	66,000	2.32%	49,976	0.00%
Ritu Mittal	1,57,769	5.23%	1,21,661	7.69%
Satish Verma	1,33,689	(3.70%)	1,59,275	0.00%



4 Reserves & Surplus			
Particulars	As at March 31, 2022	As at March 31, 2021	
Securities Premium Account			
Balances at beginning of the year	4,837.09	4,837.09	
Add: Securities Premium credited on share issue	-	-	
Balances at end of the year	4,837.09	4,837.09	
Surplus in Statement of Profit and Loss :			
Balances at beginning of the year	6,932.40	6,288.89	
Add : Profit for the Year	2,374.97	643.51	
Less: Dividend to Preference Share holders*	(0.00)	(0.00)	
	9,307.37	6,932.40	
Total	14,144.46	11,769.49	

* Amount is below the rounding off norms adopted by the Group.

5 Long-Term Borrowings			
Particulars	As at March 31, 2022	As at March 31, 2021	
Secured			
Term Loan for Medical Equipment's: (Refer note below)			
From Banks	1,104.52	826.65	
Car Loans:			
From Banks	19.24	-	
Car Loans: (Refer note below)			
From a Financial Institution	15.19	26.39	
	1,138.95	853.04	
Unsecured			
Working Capital Term Loan:			
From Banks (Refer note below)	89.18	139.81	
	89.18	139.81	
Total	1,228.13	992.85	

Details of rate of interest, repayment and securities with respect to term loans for Medical Equipment's

The aforesaid term loans are secured against the hypothecation over Medical Equipment's against which such loans has been taken and Personal Guarantee of Directors. Such loans are repayable in equal monthly instalment over a period varying from 36 months to 68 months along with interest in the range of 8.55% to 9.80% p.a.

Details of rate of interest, repayment and securities with respect to Car Loans

The aforesaid term loans are secured against the hypothecation over Vehicle's against which such loans has been taken and Personal Guarantee of Directors. Such loans are repayable in equal monthly instalment over a period of 36 months along with interest in the range of 8.25% to 9.75% p.a.

Details of rate of interest, repayment and securities with respect to Working Capital Term Loan

The aforesaid working capital term loan is unsecured and is repayable in equal monthly instalment over a period of 48 months along with interest of 8.25% p.a.

6 Deferred Tax Liabilities (Net) - Non-Current			
Particulars	As at March 31, 2022	As at March 31, 2021	
Deferred Tax Liability			
Temporary differences in carrying cost of PPE & Intangibles assets between books of accounts & tax purpose	1,062.88	1,104.91	
Gross deferred tax liability	1,062.88	1,104.91	
Deferred Tax Asset			
Expenses allowable on payment, write off, etc.	47.55	118.71	
Provision for Employee Benefits	10.62	3.29	
Gross deferred tax asset	58.17	122.00	
Net Deferred Tax Liabilities	1,004.71	982.91	

7 Long-Term Provisions			
Particulars	As at March 31, 2022	As at March 31, 2021	
Provision for employee benefits			
Gratuity (Refer Note 30)	1.05	-	
Leave	30.09	11.01	
Total	31.14	11.01	

* Amount is below the rounding off norms adopted by the Group.



8 Short-Term Borrowings

Particulars	As at March 31, 2022	As at March 31, 2021
Secured - Current maturities of Long Term Borrowings (Refer Note 5)		
Term Loan for Medical Equipments:		
From Banks	608.93	616.72
Car Loans:		
From Banks	2.69	4.06
Car Loans:		
From Financial Institution	11.56	9.53
	623.18	630.31
Unsecured - Current maturities of Long Term Borrowings (Refer Note 5)		
Working Capital Term Loan:		
From Banks	50.63	19.90
	50.63	19.90
Total	673.81	650.21

10 Other Current Liabilities

Particulars	As at March 31, 2022	As at March 31, 2021
Security deposit received from collection centres	65.53	78.31
Capital creditors	23.20	83.73
Advance from Customers	65.87	2.45
Interest accrued but not due	7.37	4.97
Employee Benefits Payable	332.37	316.18
Statutory Dues payable	133.72	89.09
Other payables	0.63	9.97
Total Other current liabilities	628.69	584.70

11 Short-Term Provisions

Particulars	As at March 31, 2022	As at March 31, 2021
Provision for income tax (net of advance tax and tax deducted at source amounting to Rs. 1549.63 lacs (March 31 2021: Rs Nil))	114.21	-
Provision for Dividend of Preference Shares*	0.00	0.00
Provision for employee benefits		
Leave	6.39	0.30
Total	120.60	0.30

* Amount is below the rounding off norms adopted by the Group.



Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Consolidated Financial Statements as at and for the year ended March 31, 2022

(all amounts in INR Lacs, unless stated otherwise)

9 Trade payables

Particulars	As at March 31, 2022	As at March 31, 2021
At amortised cost		
Total outstanding dues of micro enterprises and small enterprises	4.29	4.63
Total outstanding dues of creditors other than micro enterprises and small enterprises	1,383.03	1,255.77
Total	1,387.32	1,260.40

Based on the information available, the Group is having no outstanding dues and payments made to any supplier of goods and services beyond the specified period under Micro, Small and Medium Enterprises Development Act, 2006 [MSMED Act]. There is no interest payable or paid to any suppliers under the said Act.

9.1 Trade Payables Ageing Schedule - Based on the requirements of Amended Schedule III

Particulars	Outstanding as on March 31, 2022 from due date of payment						Total
	Unbilled Due	Not Due	Upto 1 Year	1-2 years	2-3 years	More than 3 years	
Total outstanding dues of micro enterprises and small enterprises	-	-	4.29	-	-	-	4.29
Total outstanding dues of creditors other than micro enterprises and small enterprises	68.38	985.91	242.28	86.46	-	-	1,383.03
Disputed dues of micro enterprises and small enterprises	-	-	-	-	-	-	-
Disputed dues of creditors other than micro enterprises and small enterprises	-	-	-	-	-	-	-
Total	68.38	985.91	246.57	86.46	-	-	1,387.32

Particulars	Outstanding as on March 31, 2021 from due date of payment						Total
	Unbilled Due	Not Due	Upto 1 Year	1-2 years	2-3 years	More than 3 years	
Total outstanding dues of micro enterprises and small enterprises	-	-	4.63	-	-	-	4.63
Total outstanding dues of creditors other than micro enterprises and small enterprises	68.18	756.90	178.91	251.78	-	-	1,255.77
Disputed dues of micro enterprises and small enterprises	-	-	-	-	-	-	-
Disputed dues of creditors other than micro enterprises and small enterprises	-	-	-	-	-	-	-
Total	68.18	756.90	183.54	251.78	-	-	1,260.40



12 Property, Plant & Equipment And Capital Work in Progress

Particulars	Property, Plant and Equipment										Capital Work in Progress	
	Land- Freehold (Refer note 12.3 below)	Buildings (Refer note 12.3 below)	Plant & Machinery	Computer Hardware	Furniture and Fixtures	Laboratory Equipment (Refer note 12.3 below)	Vehicles	Computer Server	Office Equipment	Total		
Gross Block												
As at March 31, 2020	79.26	974.67	977.35	637.67	3,800.12	11,787.57	368.53	60.32	328.01	19,013.50		38.24
Additions	-	-	24.00	13.67	186.33	669.41	-	-	16.89	910.30		0.86
Disposals	-	-	-	-	525.11	98.52	4.06	-	9.67	637.36		-
Transfer	-	-	-	-	38.24	-	-	-	-	38.24		(38.24)
As at March 31, 2021	79.26	974.67	1,001.35	651.34	3,499.58	12,358.46	364.47	60.32	335.23	19,324.68		0.86
Additions	-	10.40	97.60	53.11	194.36	634.21	42.12	-	30.10	1,061.90		751.59
Disposals	-	-	6.27	-	-	340.24	29.80	-	-	376.30		-
Transfer	-	-	19.25	27.12	446.98	133.88	-	-	1.70	628.94		(628.94)
As at March 31, 2022	79.26	985.07	1,111.93	731.57	4,140.92	12,786.31	376.79	60.32	367.03	20,639.20		123.51
Accumulated Depreciation												
As at March 31, 2020	-	17.26	491.94	541.28	1,371.07	3,739.28	129.03	54.93	181.35	6,526.12		-
Charge for the year	-	15.43	96.46	40.89	345.76	886.32	42.47	2.04	45.18	1,474.55		-
Disposals	-	-	-	-	268.85	87.26	2.30	-	8.91	367.32		-
As at March 31, 2021	-	32.69	588.40	582.17	1,447.98	4,538.34	169.20	56.97	217.62	7,633.37		-
Charge for the year	-	15.58	88.02	43.58	327.53	885.56	41.72	0.26	48.71	1,450.96		-
Disposals	-	4.41	-	-	-	174.70	21.32	-	-	200.43		-
As at March 31, 2022	-	48.27	672.01	625.75	1,775.51	5,249.20	189.60	57.23	266.33	8,883.90		-
Net Block												
As at March 31, 2021	79.26	941.98	412.95	69.17	2,051.60	7,820.12	195.27	3.35	117.61	11,691.31		0.86
As at March 31, 2022	79.26	936.80	439.92	105.82	2,365.41	7,537.11	187.19	3.09	100.70	11,755.30		123.51

- 12.1 Addition through Acquisitions related to cost of property, plant & equipment of two diagnostics centre's which has been acquired by the Holding Company against a Purchase Consideration of Rs. Nil (Previous Year: Rs. 6,35.98 lacs) and details are mentioned as below :

Description of Assets	Addition through Acquisitions	
	As at March 31, 2022	As at March 31, 2021
Plant & Machinery	-	11.86
Computer Hardware	-	2.65
Furniture and Fixtures	-	82.18
Laboratory Equipment	-	531.63
Office Equipment	-	7.66
Total	-	635.98

12.2 Capital Work in Progress (CWIP) ageing schedule - Based on the requirement of Amended Schedule III

As at March 31, 2022

Particulars	Amount in CWIP for the period of				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Projects in progress	123.51	-	-	-	123.51
Total	123.51	-	-	-	123.51

As at March 31, 2021

Particulars	Amount in CWIP for the period of				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Projects in progress	0.86	-	-	-	0.86
Total	0.86	-	-	-	0.86

- 12.3 The Holding Company has created a first and exclusive charge by way of mortgage over its entire land and building along with hypothecation of certain medical equipment having a net block of Rs 1,826.16 lacs (Gross Block of Rs.3,013.19 lacs) (Previous Year: Rs Nil (Gross block of Rs Nil) against personal loan taken by its director.



13 Intangible Assets

Particulars	Other Intangible Assets		Intangible assets under development
	Computer software	Total	
Gross Block			
As at March 31, 2020	433.45	433.45	-
Additions	-	-	15.05
Disposals	-	-	-
Transfer	-	-	-
As at March 31, 2021	433.45	433.45	15.05
Additions	10.57	10.57	-
Transfer	15.05	15.05	(15.05)
As at March 31, 2022	459.07	459.07	-
Accumulated Amortisation			
As at March 31, 2020	128.91	128.91	-
Charge for the year	96.61	96.61	-
Disposals	-	-	-
As at March 31, 2021	225.52	225.52	-
Charge for the year	58.17	58.17	-
Disposals	-	-	-
As at March 31, 2022	283.69	283.69	-
Net Block			
As at March 31, 2021	207.93	207.93	15.05
As at March 31, 2022	175.38	175.38	-

13.1 Intangible Assets Under Development (IAUD) Aging schedule - Based on the requirements of Amended Schedule III

As at March 31, 2022

Particulars	Amount in IAUD for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	-	-	-	-	-
Total	-	-	-	-	-

As at March 31, 2021

Particulars	Amount in IAUD for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	15.05	-	-	-	15.05
Total	15.05	-	-	-	15.05



14 Long-Term Loans & Advances

Particulars	As at March 31, 2022	As at March 31, 2021
Unsecured, considered good		
Prepaid Rent on Medical Equipments	156.79	180.00
Capital Advances	40.27	-
Total	197.06	180.00

15 Other Non-Current Assets

Particulars	As at March 31, 2022	As at March 31, 2021
Deposits with banks (Refer Note a below)	4,744.61	1,408.48
Security Deposits	745.20	705.30
Other Advances (Refer Note 31)	150.00	150.00
Advance to Gratuity Trust (Refer Note 30)	-	11.76
Total	5,639.81	2,275.54

(a) Bank deposits has been pledged by way of security for loan granted to the Holding Company or bank guarantee given, which are not encashable within next year and are renewable at the time of maturity.

16 Current Investments

Particulars	As at March 31, 2022	As at March 31, 2021
Investment in units of Mutual Funds		
HDFC Liquid Fund, Direct Daily, IDCW Plan - Nil (Previous Year : 53,066.33 units)	-	541.18
Total	-	541.18
Aggregate cost of Quoted Investment	-	541.21
Aggregate Net Asset Value of Quoted Investment	-	541.18

17 Inventories

Particulars	As at March 31, 2022	As at March 31, 2021
At cost or net realisable value, whichever is lower		
Consumable Stores	622.53	444.50
Total	622.53	444.50

19 Cash & Bank Balances

Particulars	As at March 31, 2022	As at March 31, 2021
Cash and Cash Equivalents		
In Current Accounts	213.06	219.92
Cash in hand	30.45	54.89
Prepaid Bank Balances	13.96	18.40
Other Bank Balances		
Deposits with maturity period more than three months and less than twelve months (including accrued interest)	25.00	149.83
Total	282.47	443.04

20 Short-Term Loans & Advances

Particulars	As at March 31, 2022	As at March 31, 2021
Prepaid expenses	312.49	90.39
Prepaid Rent on Medical Equipments	27.86	-
Other loans and advances		
Advance to Suppliers		
- Related Parties (Refer Note 32)	3.45	3.29
- Others	168.23	231.17
Other Advances		
- Others	6.93	16.32
Advance Income Tax and tax deducted and source (Net of provision of Rs. Nil (March 31, 2021 Rs. 1,110.10 lacs)	-	364.62
Total	518.96	705.79



Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Consolidated Financial Statements as at and for the year ended March 31, 2022
(all amounts in INR Lacs, unless stated otherwise)

18 Trade Receivables

Particulars	As at March 31, 2022	As at March 31, 2021
At amortised cost		
- Trade Receivables considered good - Secured	756.70	599.53
- Trade Receivables considered good - Unsecured	163.29	407.67
- Trade Receivables - considered doubtful - Unsecured	919.99	1,007.20
Less: Provision for doubtful debts	163.29	407.67
Total Trade receivables	756.70	599.53
Trade receivables include debts due by:		
Related Parties (Refer note 32)	133.63	71.18
Others	623.07	528.35
Total Trade receivables	756.70	599.53

Particulars	Outstanding from due date of payment as on March 31, 2022						Total
	Not Due	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed							
- considered good	226.68	307.00	194.53	19.20	9.28	-	756.70
- considered doubtful	-	-	-	124.02	39.27	-	163.29
	226.68	307.00	194.53	143.22	48.55	-	919.99
Less: Considered doubtful	-	-	-	(124.02)	(39.27)	-	(163.29)
	226.68	307.00	194.53	19.20	9.28	-	756.70
Disputed							
- considered good	-	-	-	-	-	-	-
- considered doubtful	-	-	-	-	-	-	-
Less: Considered doubtful	-	-	-	-	-	-	-
Total	226.68	307.00	194.53	19.20	9.28	-	756.70

Particulars	Outstanding from due date of payment as on March 31, 2021						Total
	Not Due	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed							
- considered good	212.23	274.43	59.41	35.66	17.80	-	599.53
- considered doubtful	-	-	-	-	284.38	123.29	407.67
	212.23	274.43	59.41	35.66	302.18	123.29	1,007.20
Less: Considered doubtful	-	-	-	-	(284.38)	(123.29)	(407.67)
	212.23	274.43	59.41	35.66	17.80	-	599.53
Disputed							
- considered good	-	-	-	-	-	-	-
- considered doubtful	-	-	-	-	-	-	-
Less: Considered doubtful	-	-	-	-	-	-	-
Total	212.23	274.43	59.41	35.66	17.80	-	599.53



Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Consolidated Financial Statements as at and for the year ended March 31, 2022

(all amounts in INR Lacs, unless stated otherwise)

21 Revenue From Operations:

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
Sale of services		
Diagnostic Service Charges and related ancillary services	22,319.25	13,951.12
Other Operating Revenues:		
Rental Income	-	27.50
Income From Manpower Supply	-	21.95
Total Income	22,319.25	14,000.57

22 Other Income

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
<u>Interest income on</u>		
Fixed Deposit	163.40	55.46
Income Tax Refund	17.73	4.22
Profit on sale of Investment	0.29	29.42
Dividend on Mutual Fund	0.64	1.46
Liabilities/Provisions no longer required, now written back	37.07	33.71
Miscellaneous Income	11.22	13.33
Total	230.34	137.60

23 Cost of Materials Consumed

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
Inventory at the beginning of the year	444.50	544.62
Add: Purchases	6,218.52	2,500.84
	6,663.02	3,045.46
Less: Inventory at the closing of the year	622.53	444.50
Total	6,040.49	2,600.96



Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Consolidated Financial Statements as at and for the year ended March 31, 2022

(all amounts in INR Lacs, unless stated otherwise)

24 Employee Benefits Expense

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
Salaries, wages and bonus (Inclusive of Director's Remuneration)	3,152.56	2,296.87
Contribution to provident and other funds (Refer Note 30)	188.13	149.94
Gratuity expenses (Refer Note 30)	31.48	27.29
Staff welfare expenses	41.77	17.99
Total	3,413.94	2,492.09

25 Finance Cost

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
Interest expense :		
on secured loan	130.99	149.98
on unsecured loan	21.57	6.04
Total	152.56	156.02

26 Depreciation and amortisation expense

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
Depreciation on Property, Plant & Equipment (Refer note 12)	1,450.96	1,474.55
Amortisation of Intangible Assets (Refer note 13)	58.17	96.61
Total	1,509.13	1,571.16

27 Other Expenses

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
Doctors Professional Fees	2,097.33	1,531.62
Sample Testing, Collection & Logistic Charges	263.35	312.25
Commission to Collection Centers	146.72	165.63
Repairs & Maintenance:		
Machinery (including medical equipment)	839.75	527.12
Others	128.63	162.28
Donation	1.35	3.54
Office Administration Expenses	479.80	410.95
Bank charges	57.81	34.30
Advertisement and sales promotion	282.19	154.16
Electricity Charges	522.30	466.69
Expense relating to Acquisition & Valuations	88.45	-
Travelling & Conveyance Charges	195.64	264.73
Telephone & Internet Charges	91.95	67.30
Insurance Charges	79.96	74.69
IT Expenses	301.47	281.08
CSR Expense	33.72	37.39
Rent (Refer Note 33)	1,793.46	1,315.25
Rent on Medical Equipments	68.39	-
Rates & Taxes	73.43	32.95
Payment to Auditors (Refer Note 29)	14.30	12.91
Net Loss on foreign currency transactions	-	6.02
Legal & Professional Fees	169.73	122.70
Membership & subscription expenses	83.82	40.83
Freight & Other Charges	18.54	20.97
Provision for doubtful debts & advances	-	284.38
Loss on disposal of property, plant & equipment	141.48	245.03
Miscellaneous Expenses	140.66	105.79
Total	8,114.23	6,680.56



Suraksha Diagnostic Private Limited
CIN:U85110WB2005PTC102265

Notes forming part of the Consolidated Financial Statements as at and for the year ended March 31, 2022
(all amounts in INR Lacs, unless stated otherwise)

28 Earning Per Share

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
Net profit after tax for the year	2,374.97	643.51
Less: Dividend to Preference Share holders*	(0.00)	(0.00)
Adjusted Net Profit after tax for the year	2,374.97	643.51
Basic Earnings per Share		
Weighted average number of ordinary shares (No. in lacs)	6.90	6.90
Nominal value of ordinary share (in Rs. Per share)	100	100
Basic earnings for ordinary shares (in Rs. per share)	344.20	93.26
Diluted earnings per share		
Weighted average number of ordinary shares	6.90	6.90
Weighted average number of ordinary shares on account of Convertible Preference Shares	1.63	1.63
	8.53	8.53
Nominal value of ordinary share (in Rs. Per share)	100	100
Diluted earnings for ordinary shares (in Rs. per share)	278.47	75.45

* Amount is below the rounding off norms adopted by the Group.

29 Payment to Auditors

Particulars	For the year ended	
	31-Mar-22	31-Mar-21
As Statutory Auditors :		
Audit Fees	12.50	11.00
Tax Audit Fees	-	-
Reimbursement of Expenses	-	-
In Other Capacity:		
Other Services	1.80	1.91
Total	14.30	12.91



30 Employee benefits

In accordance with the Accounting Standard-15 'Employee Benefits', the Group has calculated the various benefits provided to employees as under:

A. Defined contribution plans

During the period the Group has recognized the following amounts in the Statement of profit and loss:-

Particulars	For the year ended 31	For the year ended
	March 2022	31 March 2021
Employers Contribution to Provident fund	142.67	113.27
Employers Contribution to Employee State Insurance	45.46	36.66
	188.13	149.93

B. Defined benefit plans**Gratuity plan**

The Group has a defined benefit gratuity plan. Every employee who has completed five years or more of service is entitled to Gratuity on terms as per the provisions of The Payment of Gratuity Act, 1972. The Group has taken up a Group Gratuity Scheme with Life Insurance Corporation of India (LIC), 'Suraksha Diagnostic Private Limited Employees' Gratuity Fund' to meet its obligation towards gratuity.

The following tables summarize the components of net benefit expense recognized in the statement of profit and loss and the funded status and amounts recognized in the balance sheet for the plan.

(i) Actuarial assumptions:

The principle assumptions used in determining gratuity obligations for Group's plan are shown below

Particulars	For the year ended 31	For the year ended
	March 2022	31 March 2021
Discount rate (per annum)	7.30%	6.90%
Expected Rate of increase in compensation levels	5.25%	5.25%
Expected rate of return on plan assets	6.75%	6.84%
Mortality Rate	Indian Assured Lives Mortality (2012-2014)	Indian Assured Lives Mortality (2012-2014)
Retirement age	60 Years	60 Years
Average attained age	33.32 Years	34.46 Years
Withdrawal Rate (based on age %(age))		
- Upto 30 years	3%	3%
- 31 to 44 years	2%	2%
- 44 years & above	1%	1%

The estimates of future salary increase considered in actuarial valuation, takes account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.

(ii) Amount to be recognized in Balance Sheet:

Particulars	As at	As at
	31 March 2022	31 March 2021
Present value of defined benefit obligations	1.06	(11.74)
Net liability / (asset) arising from defined benefit obligations	1.06	(11.74)

(iii) Expenses recognized in Statement of Profits and Losses:

Particulars	For the year ended 31	For the year ended
	March 2022	31 March 2021
Current service cost	41.18	34.97
Interest cost	17.30	17.01
Expected return on plan assets	(17.96)	(20.46)
Net actuarial loss/(gain) recognized during the year	(9.05)	(4.22)
Total charge to Statement of Profits and Losses	31.47	27.30



(iv) Changes in the present value of the defined benefit obligation in respect of Gratuity are as follows:

Particulars	As at	As at
	31 March 2022	31 March 2021
Present value obligation as at the beginning of the year	250.76	246.47
Interest cost	17.30	17.01
Current service cost	41.18	34.97
Benefits paid	(30.39)	(36.50)
Actuarial loss/(gain) on obligations	(14.17)	(11.19)
Present value obligation as at the end of the year	<u>264.68</u>	<u>250.76</u>

(v) Changes in the fair value of plan assets:

Particulars	As at	As at
	31 March 2022	31 March 2021
Balance at the beginning of the year	262.50	281.47
Expected Return on plan assets	17.96	20.46
Actuarial loss/(gain) on plan assets	(5.12)	(6.97)
Actual Group Contributions	18.67	4.04
Benefits paid	(30.39)	(36.50)
Balance at the end of the year	<u>263.62</u>	<u>262.50</u>
Actual Return on Plan Assets	<u>12.83</u>	<u>13.50</u>

(vi) Net assets/liability and actuarial experience gain/(loss) for present benefit obligation ('PBO') and plan assets

Particulars	As at	As at
	31 March 2022	31 March 2021
Present value of obligation	264.68	250.75
Less: Fair Value of Plan assets	263.62	262.51
Net (assets)/liability	1.06	(11.76)
Experience (gain)/loss on PBO	(0.75)	(11.19)
Experience gain/(loss) on plan assets	(5.12)	(6.97)

(vii) Major Category of Plan Assets as a % of total Plan Assets

	March 31, 2022	March 31, 2021
Funds managed by Insurer	100%	100%

(viii) The Group has contributed Rs.44,41,754 to gratuity for next financial year.



Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Consolidated Financial Statements as at and for the year ended March 31, 2022

(all amounts in INR Lacs, unless stated otherwise)

31 Contingencies & Commitments
(To the extent not provided for)

i. Contingent Liability

Particulars	As at 31-Mar-2022	As at 31-Mar-2021
Claims against the Holding Company not acknowledged as debt (Refer note (a) below)	150.00	150.00
Guarantee to financial institution to the extent of security against loan taken by directors	2,842.22	-
	<u>2,992.22</u>	<u>150.00</u>

- (a) The Holding Company had given an earnest money deposit by way bank guarantee of Rs. 150.00 lacs (Previous Year - Rs. 150.00 lacs) to Bihar State Health Society in 2014-15 which had been encashed by the other party on grounds of non-compliance of the term of agreement agreed upon between them. The company has filled writ petition before the Patna High Court which is pending disposal.

ii. Commitments

Particulars	As at 31-Mar-2022	As at 31-Mar-2021
Estimated amount of contract remaining to be executed on capital account	94.10	-
Less: Capital Advance	40.27	-
Total	<u>53.83</u>	<u>-</u>



Suraksha Diagnostic Private Limited
CIN:U85110WB2005PTC102265

Notes forming part of the Consolidated Financial Statements as at and for the year ended March 31, 2022
(all amounts in INR Lacs, unless stated otherwise)

32 Related party Disclosures

In accordance with the requirement of Accounting Standard (AS)- 18 on "Related Party Disclosures" the names of the related parties where control exists /able to exercise significant influence along with the aggregate transactions/year end balances with them as identified and certified by the management are given below:

(A) List of Related parties :

Name of Related Party	Description of relationship
Dr Somnath Chatterjee (Director)	Key Managerial Person (KMP)
Ritu Mittal (Director)	Key Managerial Person (KMP)
Suraksha Diagnostic & Eye Centre Private Limited	Enterprises owned or significantly influenced by KMP
Oscar Enclave Private Limited	Enterprises owned or significantly influenced by KMP
Tinni Investments Limited	Enterprises owned or significantly influenced by KMP
R. A. Enterprises	Enterprises owned or significantly influenced by KMP
Kejriwal Constructions	Enterprises owned or significantly influenced by KMP
Sahayata Clinic LLP	Enterprises owned or significantly influenced by KMP
Pragati Kejriwal	Relative of KMP
Raghavi Mittal	Relative of KMP

(B) Details of transactions with Related Parties

Particulars	For the period ended	
	March 31, 2022	March 31, 2021
Rental income of CT Scan Machine		
Suraksha Diagnostic & Eye Centre Private Limited	-	27.50
Total	-	27.50
Income From Manpower Supply		
Suraksha Diagnostic & Eye Centre Private Limited	-	21.95
Total	-	21.95
Sale of Services		
Suraksha Diagnostic & Eye Centre Private Limited	244.10	-
Total	244.10	-
Purchase of Consumables		
R. A. Enterprise	1,536.06	958.04
Total	1,536.06	958.04
Rent Expense		
Oscar Enclave Private Limited	444.79	336.92
Kejriwal Constructions	62.19	45.70
Suresh Enterprise	31.15	29.43
Total	538.13	412.05
Professional Fees to relative of KMP		
Pragati Kejriwal	6.00	4.95
Raghavi Mittal	0.90	-
Total	6.90	4.95
Commission Paid		
Sahayata Clinic LLP	0.17	-
Total	0.17	-
Guarantee Fee		
Dr. Somnath Chatterjee	2.75	-
Ritu Mittal	5.50	-
Total	5.50	-
Loan repaid (Including Interest)		
Tinni Investment Limited	-	1.05
Total	-	1.05



Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Consolidated Financial Statements as at and for the year ended March 31, 2022
(all amounts in INR Lacs, unless stated otherwise)

(C) Receivable from & Payable to Related Parties are set out below:

Particulars	As at March 31, 2022	As at March 31, 2021
Receivable from:		
Suraksha Diagnostic & Eye Centre Private Limited (Trade Receivable)	125.38	71.18
Oscar Enclave Private Limited (Security Deposit)	114.60	114.60
Suraksha Diagnostic & Eye Centre Private Limited (Advances from Suppliers)	3.44	3.29
Sahayata Clinic LLP (Advances from Suppliers)	0.01	-
Ritu Mittal (Other Receivable)	5.50	-
Somnath Chatterjee (Other Receivable)	2.75	-
Total	251.68	189.05
Payable for:		
R.A. Enterprise (Trade Payable)	238.59	255.56
Oscar Enclave Pvt Ltd (Trade Payable)	33.92	31.71
Kejriwal Constructions (Trade Payable)	4.74	4.41
Suresh Enterprise (Trade Payable)	2.38	2.43
Dr. Somnath Chatterjee (Salary Payable)	7.88	8.12
Mrs. Ritu Mittal (Salary Payable)	7.88	8.12
Total	295.39	310.35

(D) Remuneration of Key Management Personnel

The remuneration of key management personnel and a relative of key management personnel of the Group are set out below in aggregate for each of the categories specified in AS 18 'Related party disclosures'.

Particulars	For the period ended	
	31 March 2022	31 March 2021
Salary & Allowance		
Dr. Somnath Chatterjee	144.00	92.26
Ritu Mittal	144.00	92.26
Total Director's Remuneration	288.00	184.52



33 Leases

Operating lease: Group as lessee

The Group's significant leasing arrangements are in respect of operating leases for -

- a. Premises (office, diagnostic centre's etc.) - These leasing arrangements are cancellable in nature as per the terms of individual agreement and are usually renewable on mutual consent basis. The aggregate lease rentals payable are charged as 'Rent' under Note 27.

- b. Medical Equipment – The Group has entered into leasing agreement for certain medical equipments with a vendor. These non cancellable leases are for a period of 7 years. The aggregate lease rentals payable are charged as 'Rent on medical equipment' under Note 27 (inclusive of variable rental expense of Rs. 58.04 lacs (March 31 2021 – Rs Nil)

Future minimum rentals payments under non-cancellable operating leases are as follows:

	31 March 2022	31 March 2021
Within one year	27.86	-
After one year but not more than five years	111.43	-
More than five years	45.35	-
Total	184.64	-

34 Segment Reporting

(A) Information about primary segments

The primary segment of the Group is business segment which comprises of carrying on the business of diagnostic centers for providing various pathology and radiology services. The entire operations are governed by the same set of risks and returns and hence is considered as representing a single business segment.

As the Group operates in a single primary business segment, no separate segment information has been disclosed.

(B) Segment information for secondary segment reporting (by geographical segment)

The Group's entire revenue comes from customers located in India, therefore no separate geographical segment has been presented.



Suraksha Diagnostic Private Limited

CIN:U85110WB2005PTC102265

Notes forming part of the Consolidated Financial Statements as at and for the year ended March 31, 2022
(all amounts in Rs. unless stated otherwise)

35 Additional information in respect of Net Asset and Profit/loss of each entity within the Group and their proportionate share

Particulars	As at March 31, 2022		As at March 31, 2021	
	Net Asset, i.e. Total Asset minus total Liabilities		Net Asset, i.e. Total Asset minus total Liabilities	
	% of consolidated net assets	Amount	% of consolidated net assets	Amount
Parent				
<i>Suraksha Diagnostic Private Limited</i>	100.03%	15,001.41	100.03%	12,626.31
Subsidiary				
<i>Suraksha Speciality LLP</i>	0.10%	15.07	0.08%	10.09
<i>Suraksha Salvia LLP</i>	0.08%	11.34	0.05%	6.45
	100.20%	15,027.82	100.16%	12,642.85
Intercompany elimination and consolidation adjustments	(0.20%)	(30.50)	(0.16%)	(20.50)
Total	100.00%	14,997.32	100.00%	12,622.35

Particulars	As at March 31, 2022		As at March 31, 2021	
	Share in Profit or Loss		Share in Profit or Loss	
	% of consolidated net assets	Amount	% of consolidated net assets	Amount
Parent				
<i>Suraksha Diagnostic Private Limited</i>	100.01%	2,375.10	100.61%	647.45
Subsidiary				
<i>Suraksha Speciality LLP</i>	(0.00%)	(0.02)	(0.06%)	(0.40)
<i>Suraksha Salvia LLP</i>	(0.01%)	(0.11)	(0.55%)	(3.54)
	100.00%	2,374.97	100.00%	643.51



36 Additional regulator information required by Schedule III

- a. The Group has not revalued its property, plant and equipment or intangible assets during the current or previous year.
- b. No Loans or Advances in the nature of loans are granted to promoters, directors, KMPs and the related parties (as defined under Companies Act, 2013), either severally or jointly with any other person.
- c. The Group does not have any Benami property and there are no proceedings have been initiated or pending against the Group for holding any Benami property.
- d. The Group has not borrowed any fund from banks or financial institution on the basis of security of current assets and hence there is no requirement of filing quarterly returns or statements of current assets with banks or financial institutions.
- e. The Group has not been declared wilful defaulter by any banks or financial institution or government or any government authority.
- f. The Group has no transactions with the companies struck off under Companies Act, 2013 or Companies Act, 1956
- g. The Group has complied with the number of layers prescribed under clause (87) of section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017.
- h. The Group has not entered into any scheme of arrangement which has an accounting impact on current or previous financial year.
- i. **Utilisation of Borrowed funds and share premium**
 - (i) The Group has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Group (Ultimate Beneficiaries) or
 - (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
 - (ii) The Group has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Group shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
 - (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries
- j. There is no income surrendered or disclosed as income during the current or previous year in the tax assessments under the Income Tax Act, 1961, that has not been recorded in the books of account.
- k. The Group has not traded or invested in Crypto currency or Virtual Currency during the current and previous year.



37 Disclosures pursuant to section 186 of the Companies Act 2013:

	31 March 2022	31 March 2021
Guarantee given to the extent of security to Kotak Mahindra Investments Limited against loan taken by Somnath Chaterjee and Ritu Mittal (Directors)	2842.22	-
<i>(The Holding Company has given guarantee to the extent of security provided to Kotak Mahindra Investments Ltd. against personal loan taken by Directors of the Company for Rs. 6,700 lacs (Previous Year: Rs Nil). The Holding Company has created a first and exclusive charge by way of mortgage over its entire land and building along with hypothecation of certain medical equipment owned by the Company amounting to Rs 1,826.16 lacs (Previous Year: Rs Nil))</i>		

38 The Code on Social Security 2020 ('the Code') relating to employee benefits, during the employment and post-employment, has received Presidential assent on September 28, 2020. The Code has been published in the Gazette of India. Further, the Ministry of Labour and Employment has released draft rules for the Code on November 13, 2020. However, the effective date from which the changes are applicable is yet to be notified and rules for quantifying the financial impact are also not yet issued. The Group will assess the impact of the Code and will give appropriate impact in the consolidated financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.

39 COVID Note

The management has made an assessment of impact of Covid-19 on the Company's operations, financial performance and position as at and for the year ended March 31, 2022 and has concluded that that there is no impact which is required to be recognised in the consolidated financial statements. Accordingly, no adjustments have been made to the consolidated financial statements.

40 Previous year figures

Previous year's figures have been regrouped/rearranged wherever considered necessary.

As per our report of even date
For M S K A & Associates
Chartered Accountants
CAI Firm Registration No.:105047W


Puneet Agarwal
Partner
Membership No: 064824



For and on behalf of the Board of Directors of
Suraksha Diagnostic Private Limited


Dr Somnath Chatterjee
Director
DIN: 00137075


Ritu Mittal
Director

DIN: 00165886

Place: Kolkata
Date: 30-09-2022

